|
Sign In to gain access to subscriptions and/or personal tools.
|
The endothelium in atherogenesis
B J Hunt
Department of Haematology & Lupus Unit, Guy's, St Thomas' Hospital, London SEI 7EH, UK Tel: (+44) 171 928 9292 X3505; Fax: (+44)171 928 5698 Beverley.Hunt{at}gstt.sthames.nhs.uk
The focus of this article is an overview of the endothelial changes that initiate and perpetuate the process of atherogenesis. The endothelium can undergo a series of changes which allow it to participate in the inflammatory response; this is known as endothelial cell activation (ECA). The five core changes of ECA are loss of vascular integrity; expression of leucocyte adhesion molecules; change in phenotype from antithrombotic to prothrombotic; cytokine production, and upregulation of HLA molecules. The diverse effects of ECA share a common intracellular control mechanism through the activation of the transcription factors including Nuclear Factor kB. ECA is an initiating step in atherogenesis. Modified low density lipoproteins are probably the major cause of endothelial cell activation in atherogenesis, and become especially so after oxidation, glycation (in diabetes) or incorporation in immune complexes. In antiphospholipid syndrome (APS), antiendothelial cell antibodies have been detected in up to 67% of patients. In vitro studies suggest that aPL causes ECA and thus lead to speculation that aPL by causing ECA may initiate atherogenesis. Further clinical and in vitro studies are required to address these issues.
Key Words: endothelium atheroma
Lupus, Vol. 9, No. 3,
189-193 (2000)
DOI: 10.1191/096120300678828244

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. E. Hettema, H. Bootsma, and C. G. M. Kallenberg
Macrovascular disease and atherosclerosis in SSc
Rheumatology,
May 1, 2008;
47(5):
578 - 583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Del Porto, B. Lagana, S. Lai, I. Nofroni, F. Tinti, M. Vitale, E. Podesta, A. P. Mitterhofer, and R. D'Amelio
Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis
Rheumatology,
July 1, 2007;
46(7):
1111 - 1115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R J Davies, S R Sangle, M A Khamashta, and D P D'Cruz
Antiphospholipid (Hughes) syndrome and atheroma
Lupus,
November 1, 2006;
15(11_suppl):
55 - 58.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M McMahon, J Grossman, W Chen, and B H Hahn
Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus
Lupus,
November 1, 2006;
15(11_suppl):
59 - 69.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fosbrink, F. Niculescu, V. Rus, M. L. Shin, and H. Rus
C5b-9-induced Endothelial Cell Proliferation and Migration Are Dependent on Akt Inactivation of Forkhead Transcription Factor FOXO1
J. Biol. Chem.,
July 14, 2006;
281(28):
19009 - 19018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. P. de Godoy, F. Batigalia, M. R. P. de Godoy, A. C. Brandao, and D. R. S. Souza
Anticardiolipin Antibodies as a Risk Factor of Atherosclerosis in Intermittent Claudication
Angiology,
July 1, 2004;
55(4):
357 - 359.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Reiss, N. W. Awadallah, S. Malhotra, M. C. Montesinos, E. S. L. Chan, N. B. Javitt, and B. N. Cronstein
Immune complexes and IFN-{gamma} decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages
J. Lipid Res.,
November 1, 2001;
42(11):
1913 - 1922.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|